AI주식인사이트AI Stock Insight
B

한올바이오파마

009420KOSPI의약품 제조업

56.4 / 100

Reference Date: 2026-06-10

Financial Score10.0 / 40
News Sentiment18.4 / 25
Momentum18.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Surged 17.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hanall BioPharma, established in 1973, focuses on R&D, manufacturing, and sales of synthetic and biopharmaceuticals, with a particular emphasis on developing new drugs for autoimmune diseases, eye conditions, cancer, and neurological disorders. In 2024, the company reported revenue of 138.9 billion KRW, with its subsidiary HPI handling overseas clinical trials and licensing activities.

Number of Employees

315people

Average Salary

82.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 11.934.0Point
PBR
16.87Industry Average 0.890.0Point

19.0x industry avg (risky)

ROE
-3.37Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
11.80Industry Average 12.434.0Point

In line with industry avg

Trend 2023~20252.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲7.3% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼293.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -0.8% (declining, 3yr)

Detailed News Sentiment

16 totalPositive 11Neutral 5Negative 0Average Sentiment Score 73.4

Detailed Momentum

52-week position6.0Point

52w upper range (60%)

Current 52,200Won52-week high 70,70052-week low 24,250
1-month return6.0Point

1m +17.70% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral기업지배구조보고서공시2026-06-01
  • Neutral기업설명회(IR)개최(안내공시)2026-05-28
  • Neutral[기재정정]투자판단관련주요경영사항2026-05-20
  • Neutral분기보고서 (2026.03)2026-05-15